INmuneBio
1224 Prospect Street
Suite 150
La Jolla
California
92037
United States
Tel: 858-964-3720
Website: http://www.inmunebio.com
Email: dmoss@inmunebio.com
About INmuneBio
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.LEADERSHIP:
Chief Executive Officer and Chief Medical Officer: Raymond J. Tesi
Chief Financial Officer: David Moss
Chief Scientific Officer and Chief Manufacturing Officer: Mark Lowdel
PRODUCTS:
All Products
FOLLOW INMUNEBIO:
Tweets by INmuneBio
15 articles with INmuneBio
-
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer
12/6/2022
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been invited to present data on the combination of INB03™ and trastuzumab-deruxtecan (TDxd) for treatment of HER2 positive breast cancer.
-
Although there are many mechanisms proposed that contribute to neuroinflammation and damage caused by inflammaging in the brain, INmune Bio has focused on tumor necrosis factor (TNF).
-
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
4/28/2022
INmune Bio, Inc. announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2022 and to provide a corporate update.
-
INmune Bio has announced that it has dosed the first patient in its Phase II clinical trial of XPro1595 for the treatment of neuroinflammation as a cause of Alzheimer’s Disease.
-
Today is the first day of the Alzheimer’s Association International Conference 2021 (AAIC), behind held both virtually and in person in Denver, Colorado. Here’s a look at some of today’s stories.
-
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
6/14/2021
INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that the Company has entered into a new $15 million credit facility with Silicon Valley Bank and an affiliate of SVB Financial Group.
-
INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business UpdateCompany to host conference call today, May 5, at 4:30pm ET
5/5/2021
INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today reported its financial results for the first quarter ended March 31, 2021 and provided a business update.
-
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
-
INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020
8/3/2020
INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, announced that management will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference being held August 10-11, 2020 and will also be available for 1x1 meetings.
-
INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASHCompany will host an investor conference call today at 11:00 AM ET
3/11/2020
INmune Bio, Inc. today reported its financial results for the fourth quarter and full year ended December 31, 2019 and is providing a business update.
-
INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS
2/10/2020
Grant will fund proof-of-concept studies for XPro1595 therapy LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) , an immunology company developing treatments that reprogram the patient’s innate immune system to fight disease, today announced that it has been awarded a $500,000 grant from The ALS Association .
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar
11/27/2019
INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development.
-
INmune Bio Appoints Edgardo Baracchini to Its Board of Directors, Gains Additional Licensing and Business Development Expertise
10/16/2017
INmune Bio announces the appointment of Edgardo Baracchini, PhD. to its board of directors. Dr. Baracchini.
-
INmuneBio To Present At The BIO Investor 2017 Healthcare Conference
10/12/2017